BSD Medical Inc. (NASDAQ:BSDM) which provides systems that use heat therapy to treat cancer, said it has begun a Phase I/II study using hyperthermia, delivered using either the BSD-2000 Hyperthermia System or the BSD-500 Hyperthermia System, combined with proton radiotherapy to treat patients with unresectable soft tissue sarcoma.

The study will include 28 adult patients with primary and unresectable soft tissue sarcomas of extremities and trunk, excluding abdominal tumors. The trial has been registered at ClinicalTrials.gov and is open for patient enrollment.

Studies have demonstrated that hyperthermia increases the efficacy of radiation with minimal morbidity, is especially cytotoxic for large bulky tumors, and prevents the repair of radiation induced DNA damage, it said.

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) said it has closed enrollment for the company’s second re-injection Phase 3 clinical trial looking at the safety and efficacy of NX-1207 to treat enlarged prostate, or benign prostatic hyperplasia.

The NX02-0022 study enrolled patients who had previously participated in an earlier NX-1207 BPH study. In the new trial these men received a second open-label injection of NX-1207. The study used a new lyophilized formulation of NX-1207 that has longer stability stored at room temperature. An interim analysis of the study will be reported within the next few weeks. Nymox shares were up 2.1% in recent trading at $4.80, but remain near the bottom of a 52-week range of $4.40 to $8.19.

 

Get Free Updates and Stock Alerts!

*We only send one email per week